APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Spinal Muscular Atrophy (SMA)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Drugs for Spinal Muscular Atrophy (SMA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025175 pages

Choose your research edition.

Industry ResearchDrugs for Spinal Muscular Atrophy (SMA) Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Spinal Muscular Atrophy (SMA) Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Drugs for Spinal Muscular Atrophy (SMA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Spinal Muscular Atrophy (SMA) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Spinal Muscular Atrophy (SMA) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Drugs for Spinal Muscular Atrophy (SMA) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Drugs for Spinal Muscular Atrophy (SMA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Spinal Muscular Atrophy (SMA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Spinal Muscular Atrophy (SMA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Drugs for Spinal Muscular Atrophy (SMA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for Spinal Muscular Atrophy (SMA) include Novartis, Ionis Pharmaceuticals, Genentech and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for Spinal Muscular Atrophy (SMA) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Spinal Muscular Atrophy (SMA) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Spinal Muscular Atrophy (SMA) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Spinal Muscular Atrophy (SMA) market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Spinal Muscular Atrophy (SMA) Segment by Company

Novartis

Ionis Pharmaceuticals

Genentech

Biogen

Drugs for Spinal Muscular Atrophy (SMA) Segment by Type

Oral Drugs

Injections

Drugs for Spinal Muscular Atrophy (SMA) Segment by Application

Hospital

Clinic

Other

Drugs for Spinal Muscular Atrophy (SMA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Spinal Muscular Atrophy (SMA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Spinal Muscular Atrophy (SMA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Spinal Muscular Atrophy (SMA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Spinal Muscular Atrophy (SMA) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for Spinal Muscular Atrophy (SMA) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Drugs for Spinal Muscular Atrophy (SMA) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Drugs for Spinal Muscular Atrophy (SMA) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Drugs for Spinal Muscular Atrophy (SMA) Industry Trends Table 2. Drugs for Spinal Muscular Atrophy (SMA) Industry Drivers Table 3. Drugs for Spinal Muscular Atrophy (SMA) Industry Opportunities and Challenges Table 4. Drugs for Spinal Muscular Atrophy (SMA) Industry Restraints Table 5. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers Table 9. Global Drugs for Spinal Muscular Atrophy (SMA) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Drugs for Spinal Muscular Atrophy (SMA) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Drugs for Spinal Muscular Atrophy (SMA) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers, Product Type & Application Table 13. Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Spinal Muscular Atrophy (SMA) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Drugs Table 17. Major Manufacturers of Injections Table 18. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2026) & (K Units) Table 20. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027-2032) & (K Units) Table 21. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021-2026) Table 22. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2027-2032) Table 23. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2026) & (K Units) Table 25. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027-2032) & (K Units) Table 26. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021-2026) Table 27. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Other Table 31. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2026) & (K Units) Table 33. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027-2032) & (K Units) Table 34. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021-2026) Table 35. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2027-2032) Table 36. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2026) & (K Units) Table 38. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027-2032) & (K Units) Table 39. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021-2026) Table 40. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2027-2032) Table 41. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021-2026) & (K Units) Table 43. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021-2026) Table 44. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 48. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2027-2032) & (K Units) Table 49. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 51. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2027-2032) & (K Units) Table 58. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021-2026) Table 62. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2027-2032) Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 67. Novartis Recent Development Table 68. Ionis Pharmaceuticals Company Information Table 69. Ionis Pharmaceuticals Business Overview Table 70. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 72. Ionis Pharmaceuticals Recent Development Table 73. Genentech Company Information Table 74. Genentech Business Overview Table 75. Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 77. Genentech Recent Development Table 78. Biogen Company Information Table 79. Biogen Business Overview Table 80. Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio Table 82. Biogen Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Drugs for Spinal Muscular Atrophy (SMA) Distributors List Table 86. Drugs for Spinal Muscular Atrophy (SMA) Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Drugs for Spinal Muscular Atrophy (SMA) Product Image Figure 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (2021-2032) & (K Units) Figure 5. Global Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Drugs for Spinal Muscular Atrophy (SMA) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Drugs Image Figure 9. Injections Image Figure 10. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021-2032) Figure 13. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Other Image Figure 19. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021-2032) Figure 22. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021-2032) Figure 25. North America Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021-2032) Figure 27. U.S. Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021-2032) Figure 32. Germany Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021-2032) Figure 39. China Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021-2032) Figure 47. Brazil Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Drugs for Spinal Muscular Atrophy (SMA) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Figure 58. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Figure 60. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Drugs for Spinal Muscular Atrophy (SMA) Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Drugs
  • Injections
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Novartis
  • Ionis Pharmaceuticals
  • Genentech
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Drugs for Spinal Muscular Atrophy (SMA) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Drugs for Spinal Muscular Atrophy (SMA) Market Dynamics
  1. 2.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Trends
  2. 2.2 Drugs for Spinal Muscular Atrophy (SMA) Industry Drivers
  3. 2.3 Drugs for Spinal Muscular Atrophy (SMA) Industry Opportunities and Challenges
  4. 2.4 Drugs for Spinal Muscular Atrophy (SMA) Industry Restraints
3 Drugs for Spinal Muscular Atrophy (SMA) Market by Manufacturers
  1. 3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Drugs for Spinal Muscular Atrophy (SMA) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Drugs for Spinal Muscular Atrophy (SMA) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for Spinal Muscular Atrophy (SMA) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers, Product Type & Application
  7. 3.7 Global Drugs for Spinal Muscular Atrophy (SMA) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for Spinal Muscular Atrophy (SMA) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for Spinal Muscular Atrophy (SMA) Tier 1, Tier 2, and Tier 3
4 Drugs for Spinal Muscular Atrophy (SMA) Market by Type
  1. 4.1 Drugs for Spinal Muscular Atrophy (SMA) Type Introduction
  2. 4.1.1 Oral Drugs
  3. 4.1.2 Injections
  4. 4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type
  5. 4.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021-2032)
  7. 4.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type
  9. 4.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021-2032)
  11. 4.3.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021-2032)
5 Drugs for Spinal Muscular Atrophy (SMA) Market by Application
  1. 5.1 Drugs for Spinal Muscular Atrophy (SMA) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application
  6. 5.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021-2032)
  8. 5.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021-2032)
  9. 5.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application
  10. 5.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021-2032)
  12. 5.3.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021-2032)
6 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region
  1. 6.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021-2026)
  4. 6.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region
  1. 7.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region
  2. 7.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2021-2026)
  4. 7.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2027-2032)
  5. 7.1.4 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032)
  8. 7.2.2 North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032)
  11. 7.3.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Ionis Pharmaceuticals
  8. 8.2.1 Ionis Pharmaceuticals Company Information
  9. 8.2.2 Ionis Pharmaceuticals Business Overview
  10. 8.2.3 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  12. 8.2.5 Ionis Pharmaceuticals Recent Developments
  13. 8.3 Genentech
  14. 8.3.1 Genentech Company Information
  15. 8.3.2 Genentech Business Overview
  16. 8.3.3 Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  18. 8.3.5 Genentech Recent Developments
  19. 8.4 Biogen
  20. 8.4.1 Biogen Company Information
  21. 8.4.2 Biogen Business Overview
  22. 8.4.3 Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
  24. 8.4.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Spinal Muscular Atrophy (SMA) Value Chain Analysis
  2. 9.1.1 Drugs for Spinal Muscular Atrophy (SMA) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process
  6. 9.2 Drugs for Spinal Muscular Atrophy (SMA) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Spinal Muscular Atrophy (SMA) Distributors
  9. 9.2.3 Drugs for Spinal Muscular Atrophy (SMA) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst